| 翻訳と辞書 |
| Kathryn Zoon ： ウィキペディア英語版 |
Kathryn Zoon
Kathryn C. Zoon is a U.S.-based immunologist, elected to the U.S. Institute of Medicine in 2002 for her research on human interferons.〔(【引用サイトリンク】IOM Membership Directory )〕 She currently is the scientific director of the Division of Intramural Research at the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) in Bethesda, Maryland.〔(【引用サイトリンク】NIAID Office of the Director )〕 From 1992 to 2002, Zoon was director of the FDA Center for Biologics Evaluation and Research (CBER).〔(【引用サイトリンク】ESSE GOODMAN, M.D., MPH, NAMED DIRECTOR OF CBER )〕
==Life==
Zoon, née Egloff, was born in Yonkers, New York. She obtained her B.S. ''cum laude'' from Rensselaer Polytechnic Institute in 1970 and her Ph.D. in biochemistry from Johns Hopkins University in 1976. Soon after receiving her Ph.D., she undertook a training fellowship in the NIH laboratory of Christian B. Anfinsen,〔(【引用サイトリンク】url=http://www.jbc.org/content/252/19/6585.full.pdf )〕 who had won the 1972 Nobel Prize in Chemistry.〔(【引用サイトリンク】The Nobel Prize in Chemistry 1972 )〕 It was here, in the Anfinsen-led Laboratory of Chemical Biology, that she initiated her studies on interferon, a large class of proteins called cytokines used for communication between cells to trigger the protective defenses of the immune system. In 1979 and 1980 she and her colleagues were the first to report the complete purification and partial characterization, including the terminal amino acid sequence analysis, of a human interferon alpha.〔(【引用サイトリンク】url=http://www.ncbi.nlm.nih.gov/pubmed/293665 )〕〔(【引用サイトリンク】url=http://www.ncbi.nlm.nih.gov/pubmed/7352260 )〕 The discovery helped launch the biotechnology era, including the cloning and development of new cytokine products for clinical use.〔(【引用サイトリンク】url=http://nihrecord.nih.gov/PDF_Archive/1994%20PDFs/19940301.pdf )〕
Following her NIH fellowship, Zoon moved to the FDA CBER in 1980 to continued her research on interferon; and, from 1992 to 2002, she served as CBER's director, focusing on developing policies to facilitate the development of biotechnology products, helped to advance the approval of a number of vaccines, and worked to achieve a safer blood supply.〔(【引用サイトリンク】accessdate=13 March 2015 )〕
From 2002 to 2004, Zoon was principal deputy director of the Center for Cancer Research at the NIH National Cancer Institute. In 2006 she became the first female scientific director of the NIH NIAID Division of Intramural Research, where she oversees a staff of more than 120 principal investigators who lead research groups composed of staff scientists, physicians, fellows, technical personnel, and students.〔(【引用サイトリンク】publisher=NIH )〕 This includes the NIAID-led Rocky Mountain Laboratories in Hamilton, Montana, a biosafety level 4 facility. Zoon also continues her laboratory research on structure and function of human interferons as chief of NIAID's Cytokine Biology Section.〔(【引用サイトリンク】accessdate=13 March 2015 )〕 She also is an associate editor of the Journal of Interferon & Cytokine Research〔(【引用サイトリンク】accessdate=13 March 2015 )〕 and author or co-author of more than 100 publications.〔(【引用サイトリンク】publisher=PubMed )〕 She was past president of the International Society for Interferon and Cytokine Research (2000–2001) and serves on the World Health Organization Expert Committee on Biological Standardization, the Malaria Vaccine Initiative Vaccine Science Portfolio Advisory Council, the U.S. Department of Defense Malaria Vaccine Program Scientific Advisory Board, and the U.S. Agency for International Development Vaccine Development Scientific Consultants Group.〔(【引用サイトリンク】accessdate=13 March 2015 )〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Kathryn Zoon」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|